Peregrine Capital Management LLC Sells 18,147 Shares of Artivion, Inc. $AORT

Peregrine Capital Management LLC lowered its stake in Artivion, Inc. (NYSE:AORT) by 5.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 295,721 shares of the company’s stock after selling 18,147 shares during the period. Peregrine Capital Management LLC’s holdings in Artivion were worth $13,488,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of AORT. Verition Fund Management LLC grew its position in Artivion by 1.6% during the 3rd quarter. Verition Fund Management LLC now owns 16,912 shares of the company’s stock worth $716,000 after acquiring an additional 274 shares during the last quarter. State of Alaska Department of Revenue grew its holdings in shares of Artivion by 1.8% in the third quarter. State of Alaska Department of Revenue now owns 23,294 shares of the company’s stock worth $985,000 after purchasing an additional 414 shares during the last quarter. PNC Financial Services Group Inc. grew its holdings in shares of Artivion by 6.2% in the third quarter. PNC Financial Services Group Inc. now owns 8,232 shares of the company’s stock worth $349,000 after purchasing an additional 477 shares during the last quarter. Van ECK Associates Corp increased its stake in shares of Artivion by 19.0% in the third quarter. Van ECK Associates Corp now owns 3,176 shares of the company’s stock worth $134,000 after buying an additional 506 shares during the period. Finally, Oregon Public Employees Retirement Fund raised its holdings in Artivion by 5.8% during the 3rd quarter. Oregon Public Employees Retirement Fund now owns 9,329 shares of the company’s stock valued at $395,000 after buying an additional 510 shares during the last quarter. Institutional investors own 86.37% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. LADENBURG THALM/SH SH raised shares of Artivion from a “neutral” rating to a “buy” rating and set a $42.00 price target on the stock in a report on Friday, April 10th. Wall Street Zen upgraded shares of Artivion from a “hold” rating to a “buy” rating in a report on Saturday, April 11th. Weiss Ratings raised Artivion from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, February 20th. Stifel Nicolaus set a $55.00 price target on Artivion in a research report on Thursday, March 5th. Finally, Canaccord Genuity Group dropped their price objective on Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a report on Friday, February 13th. Seven research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, Artivion has a consensus rating of “Moderate Buy” and a consensus target price of $51.00.

Artivion Trading Up 1.2%

Shares of NYSE:AORT traded up $0.43 on Thursday, hitting $36.99. The company had a trading volume of 7,175 shares, compared to its average volume of 416,903. The firm’s 50-day simple moving average is $36.73 and its two-hundred day simple moving average is $41.50. The firm has a market capitalization of $1.79 billion, a price-to-earnings ratio of 185.63 and a beta of 1.63. The company has a quick ratio of 2.62, a current ratio of 3.53 and a debt-to-equity ratio of 0.49. Artivion, Inc. has a 1 year low of $23.04 and a 1 year high of $48.25.

Artivion (NYSE:AORT) last released its quarterly earnings results on Thursday, February 12th. The company reported $0.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.03. Artivion had a net margin of 2.21% and a return on equity of 7.43%. The company had revenue of $118.30 million during the quarter, compared to the consensus estimate of $116.42 million. Artivion’s revenue was up 19.2% on a year-over-year basis. Equities analysts anticipate that Artivion, Inc. will post 0.63 earnings per share for the current fiscal year.

Insider Transactions at Artivion

In related news, EVP Lance A. Berry sold 6,316 shares of Artivion stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $37.78, for a total transaction of $238,618.48. Following the sale, the executive vice president directly owned 210,827 shares in the company, valued at $7,965,044.06. The trade was a 2.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO James P. Mackin sold 20,962 shares of the company’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $37.59, for a total value of $787,961.58. Following the completion of the sale, the chief executive officer directly owned 780,031 shares in the company, valued at approximately $29,321,365.29. The trade was a 2.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 133,043 shares of company stock worth $4,977,158 over the last quarter. Insiders own 6.30% of the company’s stock.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.